M JEAN REVUZ

Rhumatologue

RPPS 10001174860

🇫🇷 Publications académiques françaises (1)

✨ Génération du profil synthétique IA en cours…

Publications académiques en France

Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.

A randomized investigator-masked double-bind placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis
2014
ArticleChest

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa

Journal of the European Academy of Dermatology and Venereology : JEADV · 2015

📚 797 citations🎯 RCR 38.77Top 0% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

AbstractHidradenitis suppurativa/acne inversa (HS) is a chronic, inflammatory, recurrent, debilitating skin disease of the hair follicle that usually presents after puberty with painful, deep‐seated, inflamed lesions in the apocrine gland‐bearing areas of the body, most commonly the axillae, inguinal and anogenital regions. A mean disease incidence of 6.0 per 100 000 person‐years and an average prevalence of 1% has been reported in Europe. HS has the highest impact on patients' quality of life among all assessed dermatological diseases. HS is associated with a variety of concomitant and secondary diseases, such as obesity, metabolic syndrome, inflammatory bowel disease, e.g. Crohn's disease, spondyloarthropathy, follicular occlusion syndrome and other hyperergic diseases. The central pathogenic event in HS is believed to be the occlusion of the upper part of the hair follicle leading to a perifollicular lympho‐histiocytic inflammation. A highly significant association between the prevalence of HS and current smoking (Odds ratio 12.55) and overweight (Odds ratio 1.1 for each body mass index unit) has been documented. The European S1 HS guideline suggests that the disease should be treated based on its individual subjective impact and objective severity. Locally recurring lesions can be treated by classical surgery or LASER techniques, whereas medical treatment either as monotherapy or in combination with radical surgery is more appropriate for widely spread lesions. Medical therapy may include antibiotics (clindamycin plus rifampicine, tetracyclines), acitretin and biologics (adalimumab, infliximab). A Hurley severity grade‐relevant treatment of HS is recommended by the expert group following a treatment algorithm. Adjuvant measurements, such as pain management, treatment of superinfections, weight loss and tobacco abstinence have to be considered.

Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies

Journal of the American Academy of Dermatology · 2008

📚 478 citations🎯 RCR 16.45Top 1% NIH

Quality of life impairment in hidradenitis suppurativa: a study of 61 cases

Journal of the American Academy of Dermatology · 2007

📚 296 citations🎯 RCR 10.93Top 2% NIH

Cookies & analyse de trafic

M JEAN REVUZ

Pourquoi vous devez consulter ce praticien

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal37

Épidémiologie & registres4

Anti-TNF2

Pharmacovigilance2

Sclérodermie2

Essai clinique1

Lupus1

Qualité de vie / PROMs1

Recommandations1

Partager cette fiche